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Background:  A randomized  trial demonstrated  that  a high-dose  inactivated  inﬂuenza  vaccine  (IIV-HD)
was  24.2%  more  efﬁcacious  than  a standard-dose  vaccine  (IIV-SD)  against  laboratory-conﬁrmed  inﬂuenza
illness in  adults  ≥65  years.  To  evaluate  the consistency  of  IIV-HD  beneﬁts,  supplemental  analyses  explored
efﬁcacy  and  immunogenicity  by baseline  characteristics  of  special  interest.
Methods:  Double-blind,  randomized,  active-controlled,  multicenter  trial.  Adults  ≥65 years  were  random-
ized 1:1  to  receive  IIV-HD  or IIV-SD  and  followed  for 6–8  months  postvaccination  for  the  occurrence  of
inﬂuenza.  One  third  of participants  were  randomly  selected  to provide  sera  for measurement  of  hemag-
glutination  inhibition  antibody  (HAI)  titers.  Efﬁcacy  (IIV-HD  vs. IIV-SD)  against  laboratory-conﬁrmed,
protocol-deﬁned  inﬂuenza-like  illness  (PD-ILI)  and  HAI  geometric  mean  titer  (GMT)  ratios  (IIV-HD/IIV-
SD)  were  evaluated  by  age,  and  number  of high-risk  comorbid  and  frailty  conditions.
Results: Efﬁcacy  (95%  conﬁdence  intervals)  of  IIV-HD  relative  to  IIV-SD  against  laboratory-conﬁrmed  PD-
ILI was  19.7%  (0.4%;  35.4%)  for  participants  65–74  years,  32.4%  (8.1%;  50.6%)  for  those  ≥75  years,  22.1%
(3.9%;  37.0%)  for participants  with  ≥1  high-risk  comorbidity,  23.6%  (−3.2%;  43.6%)  for  those  with  ≥2
high-risk  comorbidities,  27.5%  (0.4%;  47.4%)  for  persons  with  1 frailty  condition,  23.9% (−9.0%; 47.2%)  for
those with  2 frailty  conditions,  and 16.0%  (−16.3%;  39.4%)  for those  with  ≥3  frailty  conditions.  There  was
no evidence  of vaccine  efﬁcacy  heterogeneity  within  age,  comorbidity,  and  frailty  strata  (P-values  0.351,
0.875,  and 0.838,  respectively).  HAI  GMT  ratios  were  signiﬁcantly  higher  among  IIV-HD  recipients  for  all
strains  and  across  all subgroups.
Conclusions:  Estimates  of  relative  efﬁcacy  consistently  favored  IIV-HD  over  IIV-SD.  There  was no  sig-
niﬁcant  evidence  that  baseline  age,  comorbidity,  or frailty  modiﬁed  the  efﬁcacy  of  IIV-HD  relative  to
IIV-SD.  IIV-HD  signiﬁcantly  improved  HAI  responses  for all strains  and  in  all  subgroups.  IIV-HD  is  likely
to  provide  beneﬁts  beyond  IIV-SD  for adults  ≥65  years,  irrespective  of  age  and presence  of  comorbid  or
frailty  conditions.
ublis© 2015  The  Authors.  P
. IntroductionThe high burden of inﬂuenza in adults 65 years of age or older
1,2] persists despite documented improvements in vaccination
Abbreviations: IIV-HD, high-dose inactivated inﬂuenza vaccine; HA, hemag-
lutinin; IIV-SD, standard-dose inactivated intramuscular inﬂuenza vaccine; CI,
onﬁdence interval; HAI, hemagglutination inhibition; PD-ILI, protocol-deﬁned
nﬂuenza-like illness; NP, nasopharyngeal; PCR, polymerase chain reaction; VE, vac-
ine efﬁcacy; GMTs, geometric mean titers; FAS, full analysis set; ACIP, Advisory
ommittee for Immunization Practices.
∗ Corresponding author. Tel.: +1 570 957 0745; fax: +1 570 957 0934.
E-mail address: carlos.diazgranados@sanoﬁpasteur.com (C.A. DiazGranados).
ttp://dx.doi.org/10.1016/j.vaccine.2015.07.003
264-410X/© 2015 The Authors. Published by Elsevier Ltd. This is an open access article uhed  by  Elsevier  Ltd.  This  is  an  open  access  article  under the  CC  BY license
(http://creativecommons.org/licenses/by/4.0/).
rates [3]. A high-dose inactivated inﬂuenza vaccine (IIV-HD) con-
taining four times the amount of hemagglutinin (HA) antigen per
vaccine strain compared to standard-dose inactivated intramuscu-
lar inﬂuenza vaccines (IIV-SD) was developed to address the need
for improved inﬂuenza protection in this population [4].
A recently completed trial (NCT01427309) demonstrated that
IIV-HD was  24.2% (95% conﬁdence interval [CI], 9.7%; 36.5%) more
efﬁcacious than an IIV-SD in preventing laboratory-conﬁrmed
symptomatic inﬂuenza in adults 65 years of age and older [5]. Rela-
tive efﬁcacy was higher against vaccine-similar strains (35.4% [95%
CI, 12.5%; 52.5%]). The study also demonstrated that IIV-HD induced
signiﬁcantly higher hemagglutination inhibition (HAI) antibody
responses compared to IIV-SD.
nder the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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To evaluate the consistency of IIV-HD beneﬁts, we  performed
upplemental analyses of the original study data exploring efﬁ-
acy and immunogenicity of IIV-HD compared to IIV-SD according
o participants’ baseline age, and high-risk comorbid and frailty
onditions.
. Methods
.1. Study design
Details on the original study design are available elsewhere [5].
rieﬂy, the study was a phase IIIb/IV, multicenter, randomized,
ouble-blind, active-controlled trial comparing IIV-HD vs. IIV-SD
n adults ≥65 years of age at 126 centers in the United States
nd Canada. The study was approved by three institutional review
oards and all participants gave written informed consent for study
articipation. Enrollment occurred during the falls of 2011 (year 1)
nd 2012 (year 2).
.2. Study participants
The study included medically stable (without moderate or
evere acute illness) adults ≥65 years. Participants were excluded
f they had: history of Guillain–Barré syndrome, systemic hyper-
ensitivity or life-threatening reaction to the study vaccines
r their components; received inﬂuenza vaccination within 6
onths prior to enrollment; thrombocytopenia, bleeding disor-
er, or received anticoagulants contraindicating intramuscular
accination; dementia, any cognitive condition, alcohol abuse, or
rug addiction at a stage that could interfere with study com-
liance; or were: participating or had participated in another
nterventional study within 4 weeks preceding enrollment; inves-
igators or their employees or immediate family members;
eprived of freedom. Baseline characteristics were collected at
nrollment.
.3. Vaccines
The vaccines were formulated according to the U.S. Food and
rug Administration recommendations. IIV-SD (Fluzone® vac-
ine, Sanoﬁ Pasteur, Swiftwater, PA) contained 15 g of HA per
train. IIV-HD (Fluzone High-Dose vaccine, Sanoﬁ Pasteur) con-
ained 60 g of HA per strain. Both vaccines were produced in
mbryonated chicken eggs, inactivated with formaldehyde, split
ith a nonionic detergent, and contained A/California/7/2009
H1N1), A/Victoria/210/2009 (H3N2), and B/Brisbane/60/2008
trains for the year 1 season and A/California/7/2009 (H1N1),
/Victoria/361/2011 (H3N2), and B/Texas/6/2011 (B/Wisconsin/
/2010-like virus) strains for the year 2 season. The vaccines were
rovided in 0.5-ml preﬁlled syringes and administered intramus-
ularly into the deltoid.
.4. Treatment allocation and assignment
Each study year, participants were randomly assigned 1:1 to
eceive a single dose of IIV-HD or IIV-SD. Individuals who  partici-
ated in both years were randomly assigned again to receive one
f the study vaccines during the second year. The study used con-
ealed allocation through an interactive voice response system that
entrally assigned participants based on computer-generated block
andomization. Approximately, 1/3 of participants were selected
andomly to be in the immunogenicity subset. Participants, inves-
igators, and the sponsor’s study staff were blinded.ne 33 (2015) 4565–4571
2.5. Surveillance and inﬂuenza case ascertainment
Details about illness surveillance, clinical illness deﬁnitions, and
inﬂuenza laboratory testing have been provided elsewhere [5].
Both passive and active surveillance for respiratory illnesses were
utilized. If a participant had a respiratory illness, the study site was
to collect a nasopharyngeal (NP) swab within 5 days of illness onset.
For every study participant reporting a respiratory illness, the
study sites were instructed to collect information on the occurrence
and duration of respiratory and systemic symptoms. A protocol-
deﬁned inﬂuenza-like illness (PD-ILI) was deﬁned as an acute
illness with ≥1 of the following respiratory symptoms: sore throat,
cough, sputum production, wheezing, or difﬁculty breathing; con-
current with ≥1 of the following systemic signs or symptoms:
temperature >37.2 ◦C (>99.0 ◦F), chills, tiredness, headaches, or
myalgia.
Laboratory conﬁrmation of inﬂuenza in NP specimens was
deﬁned as a positive result on tissue culture and/or polymerase
chain reaction (PCR). An HAI assay against a panel of standard fer-
ret antisera was  performed to determine whether the identiﬁed
strain in a culture-positive sample was antigenically similar to a
vaccine strain. A sample was  considered antigenically similar to
the vaccine if there was a ≤4-fold difference in the titer of the clin-
ical isolate and the vaccine strain against a reference antiserum
homologous to the vaccine. Positive samples by tissue culture or
PCR underwent genetic sequencing to determine similarity to any
vaccine component [5].
2.6. Immunogenicity
Blood samples were collected for measurement of HAI titers at a
visit approximately 28 days postvaccination in the immunogenicity
subset. HAI titers against each vaccine strain were measured using a
standard assay [6] and testing was performed by a single laboratory
(Focus Diagnostics, Inc., Cypress, CA, USA).
2.7. Baseline characteristics evaluated in subgroup analyses
Efﬁcacy and immunogenicity of IIV-HD relative to IIV-SD were
evaluated according to several baseline characteristics of study par-
ticipants.
Age. Age strata were deﬁned as participants 65-–74 years and
those 75 years and older based on age at enrollment.
High-risk comorbid conditions. The study protocol prespeciﬁed
high-risk comorbid conditions considered to increase the risk of
inﬂuenza complications [2] and included the following: asthma,
chronic obstructive lung disease, congestive heart failure, coro-
nary artery disease, valvular heart disease, atrial ﬁbrillation, sickle
cell disease, diabetes mellitus, hypothyroidism, epilepsy, stroke,
spinal cord injury, Parkinson’s disease, chronic kidney disease,
chronic hepatitis, cirrhosis, HIV/AIDS, cancer, long-term systemic
corticosteroid therapy, and other potentially immunosuppressive
therapy. Three strata were used for evaluating vaccine efﬁcacy
(VE) homogeneity according to baseline comorbidities: no high-
risk comorbidities, one high-risk comorbidity, and two or more
high-risk comorbidities. In addition, VE was summarized for par-
ticipants with one or more prespeciﬁed high-risk comorbidities.
Immunogenicity was  summarized for participants with at least one
prespeciﬁed high-risk comorbidity and for those with at least two
prespeciﬁed high-risk comorbidities.
Frailty-associated conditions. The study protocol also prespeci-
ﬁed several frailty-associated conditions based on the study by
Mitnitski et al. [7]. At the time of enrollment, the study site collected
the presence or absence of each of the following conditions, based
on participant’s self-report: vision loss, hearing loss, impaired
mobility, difﬁculty toileting, difﬁculty bathing, difﬁculty dressing,
 Vaccine 33 (2015) 4565–4571 4567
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Table 1
Distribution of baseline characteristics of interest by vaccine group.
Baseline characteristic IIV-HD n (%)
N = 15,990
IIV-SD n (%)
N = 15,993
Age
Age 65–74 years 10,581 (66.2) 10,563 (66.0)
Age ≥75 years 5409 (33.8) 5430 (34.0)
High-risk comorbidities
No high-risk comorbidities 5240 (32.8) 5241 (32.8)
1  high-risk comorbidity 5365 (33.6) 5349 (33.4)
≥2  high-risk comorbidities 5385 (33.7) 5403 (33.8)
≥1  high-risk comorbidity 10,750 (67.2) 10,752 (67.2)
Frailty-associated conditions
No frailty conditions 2129 (13.3) 2132 (13.3)
One frailty condition 4988 (31.2) 4893 (30.6)
Two frailty conditions 3970 (24.8) 4046 (25.3)
≥3  frailty conditions 4903 (30.7) 4922 (30.8)C.A. DiazGranados et al. /
ifﬁculty grooming, difﬁculty going out, skin problems, resting
remor, changes in sleep, urinary complaints, gastrointestinal prob-
ems, and hypertension. Four strata were used for evaluating VE
omogeneity based on baseline frailty: no frailty conditions, one
railty condition, two frailty conditions, and three or more frailty
onditions. Immunogenicity was summarized for participants with
hree or more frailty-associated conditions.
.8. Statistical analysis
The primary endpoint of the original study was the occurrence
f culture- or PCR-conﬁrmed inﬂuenza ≥14 days postvaccination
aused by any inﬂuenza viral type/subtype (regardless of similarity
o the vaccine) in association with a PD-ILI. Estimates of relative VE
n this supplementary analysis were obtained for each of the strata
entioned above for this endpoint and for the following additional
hree endpoints: culture-conﬁrmed inﬂuenza ≥14 days postvacci-
ation caused by any inﬂuenza viral type/subtype in association
ith a PD-ILI; culture- or PCR-conﬁrmed inﬂuenza ≥14 days post-
accination caused by an inﬂuenza strain similar to the vaccine
omponents in association with a PD-ILI; and culture-conﬁrmed
nﬂuenza ≥14 days postvaccination caused by an inﬂuenza strain
imilar to the vaccine components in association with a PD-ILI.
The original study was powered at 80% for the assessment of the
rimary objective [5].
The VE of IIV-HD relative to IIV-SD was estimated for each
ubgroup as 1 – relative risk. The CI for efﬁcacy estimates was
alculated using the Clopper–Pearson exact method for binomial
roportions [8].
Breslow–Day tests [9] were used to evaluate vaccine efﬁcacy
omogeneity across the deﬁned strata for each of the baseline char-
cteristics of interest.
For the evaluation of immunogenicity, postvaccination antibody
esponses were summarized as HAI geometric mean titers (GMTs),
MT  ratios (IIV-HD to IIV-SD), and corresponding 95% CIs. The CIs
or GMTs and GMT  ratios were calculated based on the t distri-
ution and the assumption that log(HAI titer) followed a normal
istribution.
Statistical signiﬁcance for VE and immunogenicity within each
tratum was deﬁned by a 95% CI excluding the null value (0 for
E and 1 for GMT  ratios). For the assessment of VE consistency
etween deﬁned strata, a P-value <0.05 for the Breslow–Day tests
as to indicate signiﬁcant evidence for rejecting the homogeneity
ssumption.
The full analysis set (FAS) comprised all participants who
eceived study vaccine; subjects were grouped by assigned treat-
ent at randomization (intent-to-treat). Immunogenicity analyses
ere performed on those participants in the FAS who  also belonged
o the immunogenicity subset and had a postvaccination serology
esult.
All statistical analyses were performed using SAS® Enterprise
uide 5.1 (SAS Institute, Cary, NC).
Analyses by subgroups deﬁned by baseline age and comorbid
nd frailty conditions were prespeciﬁed in a supplemental statisti-
al analysis plan before the study was unblinded.
.9. Role of the funding source
The study’s sponsor, Sanoﬁ Pasteur, had primary responsibility
or study design, data management, and statistical analyses. The
oordinating investigator of the original study (H.K.T) had a pri-
ary role in data collection and in reviewing and approving the
riginal study protocol. The decision to publish this manuscript
as taken in consultation between the sponsor and the coordinat-
ng investigator. The manuscript was drafted by the corresponding
uthor (C.A.D) and critically reviewed, edited, and approved by allIIV-HD: high-dose inﬂuenza vaccine; IIV-SD: standard-dose inﬂuenza vaccine.
Note: proportions with listed characteristics did not differ signiﬁcantly between
study groups.
the authors. No persons other than the authors played any role in
writing the manuscript.
3. Results
3.1. Participants
A total of 31,989 participants were enrolled with 15,991 ran-
domly assigned to receive IIV-HD and 15,998 randomly assigned
to receive IIV-SD. Of year 1 participants, 7645 were reenrolled and
randomly assigned again to receive one of the study vaccines in
year 2. Of the participants who  underwent randomization, 31,983
(>99.9%) received study vaccine and were included in the FAS:
15,990 in the IIV-HD group and 15,993 in the IIV-SD group.
Baseline clinical and demographic characteristics were well bal-
anced between groups [5]. In both the groups, the mean age was
73.3 years, 56%–57% of participants were female, and approxi-
mately 74% had received inﬂuenza vaccination during the previous
season. The frequencies of the prespeciﬁed baseline characteristics
of interest were closely similar for both vaccine groups (Table 1 and
Supplementary Table in the online appendix).
3.2. Efﬁcacy
Relative VE point estimates for all subgroups of baseline char-
acteristics of interest and for all endpoints were positive, favoring
IIV-HD over IIV-SD (Tables 2 and 3 ).
For the primary endpoint of culture- or PCR-conﬁrmed inﬂuenza
PD-ILI caused by any inﬂuenza viral type/subtype (regardless of
similarity to the vaccine), IIV-HD was signiﬁcantly more effective
than IIV-SD for both age strata (65–74 years and ≥75 years), for par-
ticipants with no high-risk comorbidities and those with at least
one high-risk comorbidity, and for individuals with one frailty-
associated condition. Relative VE point estimates for the endpoint
of culture-conﬁrmed inﬂuenza PD-ILI caused by any inﬂuenza viral
type/subtype (regardless of similarity to the vaccine) were com-
parable to those of the primary endpoint, but estimates were less
precise and signiﬁcance was  observed only for the cohort of partic-
ipants 75 years of age and older and for participants with at least
one high-risk comorbidity (Table 2).
For 15 of 20 comparisons, relative VE point estimates were
higher when the analyses were restricted to inﬂuenza isolates clas-
siﬁed as similar to the vaccine components (Table 3). Although
CIs for the estimates were wider, VE was  statistically signiﬁcantly
higher for IIV-HD for 6 of the 20 comparisons.
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Table 2
Efﬁcacy of high-dose inﬂuenza vaccine (IIV-HD) relative to standard-dose inﬂuenza vaccine (IIV-SD) against conﬁrmed inﬂuenza caused by any viral type/subtype (regardless of similarity to the vaccine), associated with a
protocol-deﬁned inﬂuenza-like illness.
Laboratory-Conﬁrmed Inﬂuenza
(Positive PCR and/or Culture)
Culture-Conﬁrmed Inﬂuenza
Baseline Characteristic IIV-HD
n/N (%)
IIV-SD
n/N (%)
Relative
Efﬁcacy%
(95% CI)
P-Valuea IIV-HD
n/N (%)
IIV-SD
n/N (%)
Relative
Efﬁcacy%
(95% CI)
P-Valuea
Age
Age 65–74 years 156/10,581 (1.47) 194/10,563 (1.84) 19.7 (0.4; 35.4)
0.351
143/10,581 (1.35) 174/10,563 (1.65) 18.0 (−3.0; 34.7)
0.313Age  ≥75 years 72/5409 (1.33) 107/5430 (1.97) 32.4 (8.1; 50.6) 63/5409 (1.16) 94/5430 (1.73) 32.7 (6.4; 51.9)
High-risk comorbidities
No high-risk comorbidities 66/5240 (1.26) 93/5241 (1.77) 29.0 (1.6; 49.0)
0.875
60/5240 (1.15) 84/5241 (1.60) 28.6 (−0.7; 49.6)
0.873
One  high-risk comorbidity 82/5365 (1.53) 103/5349 (1.93) 20.6 (−7.1; 41.3) 74/5365 (1.38) 93/5349 (1.74) 20.7 (−8.8; 42.3)
≥2  high-risk comorbidities 80/5385 (1.49) 105/5403 (1.94) 23.6 (−3.2; 43.6) 72/5385 (1.34) 91/5403 (1.68) 20.6 (−9.3; 42.5)
......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
≥1  high-risk comorbidity 162/10,750 (1.51) 208/10,752 (1.93) 22.1 (3.9; 37.0) 146/10,750 (1.36) 184/10,752 (1.71) 20.6 (0.8; 36.6)
Frailty-associated conditions
No  frailty conditions 29/2129 (1.36) 44/2132 (2.06) 34.0 (−7.9; 60.2)
0.838
26/2129 (1.22) 41/2132 (1.92) 36.5 (−6.3; 62.7)
0.830
One  frailty condition 71/4988 (1.42) 96/4893 (1.96) 27.5 (0.4; 47.4) 65/4988 (1.30) 84/4893 (1.72) 24.1 (−6.2; 45.9)
Two  frailty conditions 56/3970 (1.41) 75/4046 (1.85) 23.9 (−9.0; 47.2) 49/3970 (1.23) 64/4046 (1.58) 22.0 (−15.0; 47.3)
≥3  frailty conditions 72/4903 (1.47) 86/4922 (1.75) 16.0 (−16.3; 39.4) 66/4903 (1.35) 79/4922 (1.61) 16.1 (−17.8; 40.4)
PCR: polymerase chain reaction; CI: conﬁdence interval; n: subjects with speciﬁed illness; N: subjects in the full analysis set (intent-to-treat).
a P-value against hypothesis of homogeneity in vaccine efﬁcacy across strata deﬁned by baseline characteristics, by Breslow–Day test.
Table 3
Efﬁcacy of high-dose inﬂuenza vaccine (IIV-HD) relative to standard-dose inﬂuenza vaccine (IIV-SD) against conﬁrmed inﬂuenza caused by strains similar to the vaccine components, associated with a protocol-deﬁned inﬂuenza-like
illness.
Baseline characteristic Laboratory-conﬁrmed inﬂuenzaa
(Positive PCR and/or Culture)
Culture-conﬁrmed inﬂuenzab
IIV-HD
n/N (%)
IIV-SD
n/N (%)
Relative
Efﬁcacy%
(95% CI)
P-Valuec IIV-HD
n/N (%)
IIV-SD
n/N (%)
Relative
Efﬁcacy%
(95% CI)
P-Valuec
Age
Age 65–74  years 47/10,581 (0.44) 72/10,563 (0.68) 34.8 (4.6; 55.9)
0.940
40/10,581 (0.38) 58/10,563 (0.55) 31.2 (−4.8; 55.2)
0.967Age  ≥75  years 26/5409 (0.48) 41/5430 (0.76) 36.3 (−6.6; 62.6) 23/5409 (0.43) 34/5430 (0.63) 32.1 (−18.7; 61.8)
High-risk comorbidities
No high-risk comorbidities 22/5240 (0.42) 35/5241 (0.67) 37.1 (−10.2; 64.9)
0.357
20/5240 (0.38) 30/5241 (0.57) 33.3 (−21.4; 64.1)
0.292
One  high-risk comorbidity 21/5365 (0.39) 42/5349 (0.79) 50.1 (13.9; 72.0) 17/5365 (0.32) 34/5349 (0.64) 50.1  (8.3; 73.9)
≥2  high-risk comorbidities 30/5385 (0.56) 36/5403 (0.67) 16.4 (−39.6; 50.3) 26/5385 (0.48) 28/5403 (0.52) 6.8  (−64.8; 47.5)
......................................................................................................................................................................................................................................................................................................................................................................................................................................................................................
≥1  high-risk comorbidity 51/10,750 (0.47) 78/10,752 (0.73) 34.6 (5.7; 55.0) 43/10,750 (0.40) 62/10,752 (0.58) 30.6  (−4.0; 54.1)
Frailty-associated conditions
No  frailty conditions 9/2129 (0.42) 22/2132 (1.03) 59.0 (7.4; 83.4)
0.280
8/2129 (0.38) 20/2132 (0.94) 59.9 (5.1; 84.7)
0.463
One  frailty condition 18/4988 (0.36) 35/4893 (0.72) 49.6 (8.5; 73.1) 18/4988 (0.36) 26/4893 (0.53) 32.1 (−28.7; 64.9)
Two  frailty conditions 22/3970 (0.55) 25/4046 (0.62) 10.3 (−65.7; 51.8) 18/3970 (0.45) 20/4046 (0.49) 8.3  (−82.6; 54.3)
≥3  frailty conditions 24/4903 (0.49) 31/4922 (0.63) 22.3 (−36.8; 56.4) 19/4903 (0.39) 26/4922 (0.53) 26.6 (−37.8; 61.6)
PCR: polymerase chain reaction; CI: conﬁdence interval; n: subjects with speciﬁed illness; N: subjects in the full analysis set (intent-to-treat).
a For laboratory-conﬁrmed inﬂuenza assessments, similarity was determined by ferret antigenicity testing complemented by genetic sequencing.
b For culture-conﬁrmed inﬂuenza assessments, similarity was determined solely by the ferret antigenicity testing method.
c P-value against hypothesis of homogeneity in vaccine efﬁcacy across strata deﬁned by baseline characteristics, by Breslow–Day test.
C.A. DiazGranados et al. / Vacci
Table  4
Hemagglutination inhibition (HAI) geometric mean titers (GMTs) of high-dose inﬂuenza
viral  types and subtypes contained in the vaccine.
Vaccine strain Baseline characteristic IIV-H
N 
A/California/7/2009 (H1N1)a,b,c Age 65–74 years 3540
Age  ≥75 years 1714
≥1  high-risk comorbidity 3518
≥2  high-risk comorbidities 1752
≥3  frailty conditions 1601
A/Victoria/210/2009 (H3N2)a Age 65–74 years 1609
Age  ≥75 years 766
≥1  high-risk comorbidity 1639
≥2  high-risk comorbidities 849
≥3  frailty conditions 825
A/Victoria/361/2011 (H3N2)b Age 65–74 years 1931
Age  ≥ 75 years 948
≥1  high-risk comorbidity 1879
≥2  high-risk comorbidities 903
≥3  frailty conditions 776
B/Brisbane/60/2008a Age 65–74 years 1609
Age  ≥75 years 766
≥1  high-risk comorbidity 1639
≥2  high-risk comorbidities 849
≥3  frailty conditions 825
B/Texas/6/2011b Age 65–74 years 1931
Age  ≥ 75 years 948
≥1  high-risk comorbidity 1879
≥2  high-risk comorbidities 903
≥3  frailty conditions 776
C subse
ooled.
e
i
e
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O
H
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(
a
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n
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t
“
n
c
d
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w
wI: conﬁdence interval; N: subjects in the full analysis set and the immunogenicity 
a Year 1 vaccine strain.
b Year 2 vaccine strain.
c As the H1N1 vaccine strain was the same for year 1 and year 2, the data were p
None of the 12 Breslow–Day tests (one test for each of the four
ndpoints evaluating the three baseline variables) revealed signif-
cant evidence of heterogeneity of the relative VE across strata for
ach baseline characteristic of interest (Tables 2 and 3).
.3. Immunogenicity
IIV-HD was associated with signiﬁcantly higher GMTs than IIV-
D for all strains and for all subgroups of interest (Table 4 and Fig. 1).
verall, postvaccination GMTs tended to be highest against the
3N2 component of the vaccine in year 1 (A/Victoria/210/2009)
nd lowest against the B component of the vaccine in year 2
B/Texas/6/2011).
GMT  ratios (IIV-HD–IIV-SD) ranged between 1.24 and 2.09, with
ll estimates showing lower limits of the CIs above the null value
Fig. 1). GMT  ratios tended to be highest for H3N2 vaccine compo-
ents and lowest for B vaccine components.
. Discussion
Although vaccination currently represents the most effective
ntervention in preventing inﬂuenza and its complications [2,10],
ntibody response and protection elicited by standard inﬂuenza
accines are lower in persons 65 years of age and older com-
ared to younger adults [11–13]. This is believed to be related
o changes associated with aging of the immune system or
immune senescence” [14,15]. Immune senescence encompasses
ot only immunologic deterioration that occurs with advancing
hronological age, but also other age-related events, including the
evelopment and accumulation of chronic comorbid illnesses and
railty conditions. Both illness and functional impairment increase
ith age, but persons with the same chronological age may  vary
idely in health and function [16].ne 33 (2015) 4565–4571 4569
 vaccine (IIV-HD) and standard-dose inﬂuenza vaccine (IIV-SD) against inﬂuenza
D IIV-SD
GMT
(95% CI)
N GMT
(95% CI)
 466.2 (448.2; 485.0) 3453 263.7 (252.5; 275.4)
 388.2 (366.2; 411.5) 1801 216.8 (203.5; 230.9)
 451.0 (433.1; 469.7) 3561 243.6 (233.2; 254.6)
 461.6 (435.3; 489.5) 1776 255.8 (240.1; 272.5)
 429.7 (405.0; 456.0) 1633 241.0 (225.9; 257.1)
 729.1 (685.8; 775.1) 1596 349.5 (328.4; 372.0)
 602.3 (549.5; 660.3) 786 350.6 (318.9; 385.4)
 667.4 (627.5; 709.7) 1646 336.1 (315.8; 357.6)
 684.3 (628.7; 744.9) 849 330.8 (302.9; 361.2)
 649.8 (596.8; 707.5) 853 338.2 (310.2; 368.7)
 468.5 (444.6; 493.7) 1857 269.0 (254.4; 284.5)
 443.1 (411.9; 476.6) 1015 225.6 (209.1; 243.4)
 467.3 (443.0; 493.0) 1915 245.7 (232.4; 259.7)
 456.9 (423.4; 493.1) 927 243.7 (224.9; 264.2)
 456.2 (420.4; 495.0) 780 239.9 (220.8; 260.8)
 130.3 (123.5; 137.6) 1596 86.2 (81.7; 91.0)
 155.8 (144.8; 167.6) 786 125.4 (116.0; 135.6)
 138.3 (131.2; 145.8) 1646 100.8 (95.5; 106.5)
 146.7 (136.3; 157.9) 849 110.7 (102.8; 119.2)
 145.0 (134.7; 156.1) 853 105.0 (97.6; 112.9)
 97.7 (93.2; 102.3) 1857 61.6 (58.6; 64.7)
 99.3 (92.9; 106.2) 1015 62.2 (58.4; 66.2)
 104.8 (99.9; 110.0) 1915 63.3 (60.3; 66.4)
 113.7 (106.1; 121.9) 927 66.1 (61.7; 70.9)
 104.7 (96.8; 113.2) 780 65.2 (60.7; 70.1)
t with at least one HAI assay result for the year(s)
The results of this supplementary analysis provide reassurance
that the efﬁcacy and immunogenicity beneﬁts of IIV-HD over IIV-SD
that were observed for the entire study cohort [5] remain consistent
across different subgroups of special interest.
It has been shown that among adults 65 years of age and older,
inﬂuenza-associated hospitalization rates increase dramatically
with increasing age [1]. Studies have also indicated that effective-
ness of standard inﬂuenza vaccines decreases in older adults as age
increases [12]. Both factors play an important role in the dispropor-
tionate burden of inﬂuenza that is observed with increasing age.
The supplementary efﬁcacy analysis reported herein showed that
IIV-HD provided signiﬁcantly better protection than IIV-SD against
laboratory-conﬁrmed PD-ILI in both age strata of older adults. These
data derived from a randomized, controlled trial greatly reafﬁrm
the results of a recently published large retrospective cohort study
that reported similar estimates of vaccine effectiveness in adults
65–74, 75–84, and ≥85 years of age [17].
The dramatic increase in rates of serious inﬂuenza illness in
older adults is thought to be due in part to the rising prevalence
of high-risk conditions for inﬂuenza illness and its complications
in this population [1,14]. A previous epidemiologic study reported
that death rates from inﬂuenza and pneumonia in adults ≥65
years of age increased from 9 per 100,000 population for those
with no high-risk comorbidity to 217 per 100,000 population for
those with one high-risk comorbidity and to 797 per 100,000
population for those with two  or more high-risk comorbidities
[18]. Prior to recommending universal inﬂuenza immunization
for individuals 6 months of age and older, the United States
Advisory Committee for Immunization Practices (ACIP) recom-
mended inﬂuenza vaccination in individuals considered to be at
high risk for inﬂuenza complications, including those with chronic
cardiopulmonary, renal, metabolic, hematologic, or immunosup-
pressive conditions [2]. The high-risk comorbid illnesses evaluated
4570 C.A. DiazGranados et al. / Vaccine 33 (2015) 4565–4571
Vaccine Strain  Subgroup   GMT rao 
(95%CI) 
Forest Plot 
A/Calif ornia/7/2009 
(H1N1)*^ 
65–74  ye ars  1.77 ( 1.67;  1.87) 
≥ 75  ye ars  1.79 ( 1.64;  1.95) 
≥1 high-risk comorbidity 1.85 (1.74; 1.97) 
≥2 high- ris k co morbidi es 1.80  (1.66 ; 1.97)  
≥3 frail ty condion s  1.78 (1.63; 1.95) 
A/Victoria/210/2009 
(H3N2)* 
65–74  ye ars  2.09 ( 1.91;  2.28) 
≥ 75  ye ars  1.72 ( 1.51;  1.96) 
≥1 high- ris k co morbidi ty 1.99  (1.82 ; 2.17)  
≥2 high- ris k co morbidi es 2.07  (1.83 ; 2.34)  
≥3 frailty condions  1.92 ( 1.70;  2.17) 
A/Victoria/361/2011 
(H3N2)^ 
65–74  ye ars  1.74 ( 1.61;  1.88) 
≥ 75  ye ars  1.96 ( 1.77;  2.18) 
≥1 high- ris k co morbidi ty 1.90  (1.76 ; 2.05)  
≥2 high- ris k co morbidi es 1.87  (1.68 ; 2.09)  
≥3 frailty condions  1.90 ( 1.69;  2.14) 
B/Brisbane/60/2008* 65 –74  ye ars  1.51 ( 1.40;  1.63) 
≥ 75  ye ars  1.24 ( 1.12;  1.38) 
≥1 high- ris k co morbidi ty 1.37  (1.27 ; 1.48)  
≥2 high- ris k co morbidi es 1.33  (1.19 ; 1.47)  
≥3 frailty condions  1.38 ( 1.25;  1.53) 
B/Texas/6/2011^ 65 –74  ye ars  1.59 ( 1.48;  1.70) 
≥ 75  ye ars  1.60 ( 1.46;  1.75) 
≥1 high- ris k co morbidi ty 1.66  (1.55 ; 1.77)  
≥2 high- ris k co morbidi es 1.72  (1.56 ; 1.90)  
≥3 frailty condions  1.60 ( 1.44;  1.78) 
GMT Ratio: IIV-HD / IIV-SD
1.0 1. 5 2. 0 2.5
Fig. 1. HAI antibody GMT  ratios (IIV-HD to IIV-SD) for vaccine strains.
( As the
p  repre
A hat do
a
h
c
s
c
s
o
t
i
e*) Corresponds to a year 1 vaccine strain; ()ˆ corresponds to a year 2 vaccine strain. 
lot  on the right depicts GMT  ratios for each subgroup of interest; horizontal lines
ll  estimates to the right of the null value of 1 favor IIV-HD over IIV-SD. Estimates t
t baseline in this study closely corresponded to those that ACIP
as traditionally considered high risk for inﬂuenza and its compli-
ations. Previous studies have suggested that the effectiveness of
tandard inﬂuenza vaccines is lower in adults with these high-risk
omorbidities than in those without them [19–21]. Notably, this
upplementary analysis suggests that the 24.2% improved efﬁcacy
f IIV-HD over IIV-SD in preventing laboratory-conﬁrmed PD-ILI
hat was observed for the entire cohort [5] is generally maintained
n individuals with baseline high-risk comorbidities: the relative
fﬁcacy observed in this supplementary analysis was 22.1% for H1N1 vaccine strain was the same for year 1 and year 2, the data were pooled. The
sent the 95% conﬁdence intervals and solid squares represent the point estimates.
 not intersect with the null value are statistically signiﬁcant.
individuals with at least one high-risk comorbid condition and
23.6% for those with 2 or more high-risk comorbidities.
In community-dwelling older adults, frailty is associated with
impairment of vaccine-induced antibody response and increased
risk of breakthrough inﬂuenza infection [22]. Therefore, it has been
suggested that evaluating frailty status in the elderly may  identify
those who  are less likely to respond to inﬂuenza immunization and
be at higher risk for inﬂuenza and its complications. Our analysis
of strata encompassing one, two, or three or more baseline frailty
conditions consistently favored IIV-HD over IIV-SD, with relative
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fﬁcacy point estimates ranging between 16.0% and 27.5% against
ny inﬂuenza strain regardless of similarity to the vaccine, and
etween 8.3% and 49.6% against inﬂuenza strains similar to the
accine components.
Importantly, our results revealed no signiﬁcant evidence of
accine efﬁcacy modiﬁcation by increasing age, high-risk comor-
idities, or frailty.
Overall, the supplementary immunogenicity analyses pre-
ented here demonstrate that IIV-HD signiﬁcantly improved HAI
esponses for all strains and in all subgroups during both study
ears.
This supplementary report has important limitations. The orig-
nal study was not powered to address the objectives of this
upplementary analysis. Therefore, some estimates presented here
or independent strata do not have sufﬁcient precision to demon-
trate statistical signiﬁcance. Although the original study allowed
nclusion of individuals with high-risk comorbidities and frailty
onditions, participants were excluded if they had moderate or
evere acute illnesses or if they were judged unable to comply
ith study procedures. Extrapolation of study results to such indi-
iduals should be made with caution. Additionally, the high-risk
omorbidities prespeciﬁed in the study are unlikely to represent a
omogenous level of risk for inﬂuenza complications. Depending
n factors such as type of condition and its stage, medical treat-
ent, and severity, the risk may  range from minimal to very high.
ccordingly, classifying individuals into a single group without tak-
ng these factors into account may  have decreased the ability to
etect differences in subsets of low to high risk. Finally, this supple-
entary analysis evaluated several associations without correcting
or multiplicity. Therefore, even statistically signiﬁcant effects need
rudent interpretations.
In conclusion, this supplementary analysis suggests that IIV-HD
s likely to provide beneﬁts beyond IIV-SD to all adults ≥65 years,
rrespective of age, presence of comorbidities, or frailty-associated
onditions.
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